Publications | Centro de Investigaciones Biológicas Margarita Salas - CIB Margarita Salas

Back

Ginex, T.; Garaigorta, U.; Ramírez, D.; Castro, V.; Nozal, V.; Maestro, I.; García-Cárceles, J.; Campillo, N. E.; Martinez, A.; Gastaminza, P.; Gil, C. [2021]. Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical in silico/in vitro screening methods. Pharmaceuticals 2021, 14, 332.

Benítez-Fernández, R.; Melero-Jerez, C.; Gil, C.; de la Rosa, E. J.; Martinez, A.; de Castro, F. [2021]. Dynamics of central remyelination and treatment evolution in a model of multiple sclerosis with optic coherence tomography. Int J Mol Sci 2021, 22, 2440.

Nozal, V.; Rojas-Prats, E.; Maestro, I.; Gil, C.; Pérez, D. I.; Martinez A. [2021]. Improved controlled release and brain penetration of the small molecule S14 using PLGA nanoparticles. Int J Mol Sci 2021, 22, 3206.

Gallego, V.; Naveiro, R.; Roca, C.; Ríos Insua, D.; Campillo, N. E. [2021]. AI in drug development: a multidisciplinary perspective. Mol Divers 2021, 25 (3), 1461-1479.

Jimenez, M.; Campillo, N. E.; Canelles, M. [2021]. COVID-19 Vaccine race: Analysis of age-dependent immune responses against SARS-CoV-2 indicates that more than just one strategy may be needed. Curr Med Chem 2021, 28 (20), 3964-3979.

Davies, M. P.; Benitez, R.; Perez, C.; Jakupovic, S.; Welsby, P.; Rzepecka, K.; Alder, J.; Davidson, C.; Martinez, A.; Hayes, J. M. [2021]. Structure-based design of potent selective nanomolar type-II inhibitors of glycogen synthase kinase-3β. J Med Chem 2021, 64 (3), 1497-1509.

Martínez-González, L.; Gonzalo-Consuegra, C.; Gómez-Almería, M.; Porras, G.; de Lago, E.; Martín-Requero, Á.; Martínez, A. [2021]. Tideglusib, a non-ATP competitive inhibitor of GSK-3β as a drug candidate for the treatment of amyotrophic lateral sclerosis. Int J Mol Sci 2021, 22 (16), 8975.

Rojas-Prats, E.; Tosat-Bitrián, C.; Martínez-González, L.; Nozal, V.; Pérez, D. I.; Martínez, A. [2021]. Increasing brain permeability of PHA-767491, a cell division cycle 7 kinase inhibitor, with biodegradable polymeric nanoparticles. Pharmaceutics 2021, 13 (2), 180.

Lastres-Becker, I.; Porras, G.; Arribas-Blázquez, M.; Maestro, I.; Borrego-Hernández, D.; Boya, P.; Cerdán, S.; García-Redondo, A.; Martínez, A.; Martin-Requero, Á. [2021]. Molecular alterations in sporadic and SOD1-ALS immortalized lymphocytes: Towards a personalized therapy. Int J Mol Sci 2021, 22 (6), 3007.

Rico, A.; Guembelzu, G.; Palomo, V.; Martínez, A.; Aiastui, A.; Casas-Fraile, L.; Valls, A.; López de Munain, A.; Sáenz, A. [2021]. Allosteric modulation of GSK-3β as a new therapeutic approach in limb girdle muscular dystrophy R1 calpain 3-related. Int J Mol Sci 2021, 22 (14), 7367

Madruga, E.; Maestro, I.; Martínez, A. [2021]. Mitophagy modulation, a new player in the race against ALS. Int J Mol Sci 2021, 22 (2), 740.

Maestro, I.; de la Ballina, L. R.; Simonsen, A.; Boya, P.; Martinez, A. [2021]. Phenotypic assay leads to discovery of mitophagy inducers with therapeuticpPotential for Parkinson's disease. ACS Chem Neurosci 2021, 12 (24), 4512-4523.

Grieco, I.; Bissaro, M.; Tiz, D. B.; Perez, D. I.; Perez, C.; Martinez, A.; Redenti, S.; Mariotto, E.; Bortolozzi, R.; Viola, G.; Cozza, G.; Spalluto, G.; Moro, S.; Federico, S. [2021]. Developing novel classes of protein kinase CK1δ inhibitors by fusing [1,2,4]triazole with different bicyclic heteroaromatic systems. Eur J Med Chem 2021, 216, 113331.

Palomo, V.; Nozal, V.; Rojas-Prats, E.; Gil, C.; Martinez, A. [2021]. Protein kinase inhibitors for Amyotrophic Lateral Sclerosis therapy. Br J Pharmacol 2021, 178, 1316-1335.

Rojas-Prats, E.; Martinez-Gonzalez, L.; Gonzalo-Consuegra, C.; Liachko, N. F.; Perez, C.; Ramírez, D.; Kraemer, B. C.; Martin-Requero, Á.; Perez, D. I.; Gil, C.; de Lago, E.; Martinez, A. [2021]. Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis. Eur J Med Chem 2021, 210, 112968.

Canal-Martín, A.; Pérez-Fernández, R. [2020]. Protein-directed dynamic combinatorial chemistry: An efficient strategy in drug design. ACS Omega 2020, 5, 26307-26315.

Zaldivar-Diez, J.; Li, L.; Garcia, A. M.; Zhao, W.-N.; Medina-Menendez, C.; Haggarty, S. J.; Gil, C.; Morales, A. V.; Martínez, A. [2020]. Benzothiazole-based LRRK2 inhibitors as Wnt enhancers and promoters of oligodendrocytic fate. J. Med. Chem. 2020, 63, 2638-2655.

Gil, C.; Ginex, T.; Maestro, I.; Nozal, V.; Barrado-Gil, L.; Cuesta-Geijo, M. A.; Urquiza, J.; Ramirez, D.; Alonso, C.; Campillo, N. E.; Martinez, A. [2020]. COVID-19: Drug targets and potential treatments. J Med Chem 2020, 63, 12359-12386.

Martinez-Gonzalez, L.; Rodríguez-Cueto, C.; Cabezudo, D.; Bartolome, F.; Andrés-Benito, P.; Ferrer, I.; Gil, C.; Martin-Requero, A.; Fernández-Ruiz, J.; Martinez, A.; de Lago, E. [2020]. Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment. Sci. Rep. 2020, 10, 4449.

Castro-Sánchez, S.; Zaldivar-Diez, J.; Luengo, E.; López, M. G.; Gil, C.; Martínez, A.; Lastres-Becker, I. [2020]. Cognitive enhancement, tau phosphorylation reduction and neuronal protection by the treatment of a LRRK2 inhibitor in a tauopathy mouse model. Neurobiol. Aging 2020, 96, 148-154.